Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Errata to this article were published (Lancet Diabetes Endocrinol, Mar 2024 ↗ · Nov 2024 ↗)
Primary result · Chronic eGFR slopeResult — go to the resultRelative difference 50% 95% CI 42–58Authors' conclusion
Empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the EMPA-KIDNEY trial, including those with little albuminuria. Albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor.
Study context
- Population
- Adults ≥18 years with estimated glomerular filtration rate (eGFR) 20 to <45 mL/min per 1.73 m², or eGFR 45 to <90 mL/min per 1.73 m² with urinary albumin-to-creatinine ratio (uACR) ≥200 mg/g; 241 centres in 8 countriesmedian follow-up 2.0 years
- Participants
- 6,609 adults
- Comparison
- Empagliflozin 10 mg once daily vs placebo
- Primary endpoint
- Annualised rate of change in eGFR (eGFR slope; tertiary outcome): acute slope (randomisation to 2 months) and chronic slope (from 2 months onwards)
Methodological detailscontrolled, phase 3, multicentre (241 centres, 8 countries), intention-to-treat, shared parameter models, Randomised May 15, 2019 to April 16, 2021; median follow-up 2.0 years (IQR 1.5-2.4)
- Controlled
- Phase 3
- Multicentre (241 centres, 8 countries)
- Intention-to-treat
- Shared parameter models
- Randomised May 15, 2019 to April 16, 2021; median follow-up 2.0 years (IQR 1.5-2.4)
Primary result
Chronic eGFR slope · from 2 months onwards
Relative difference
50%
95% CI 42–58
Empagliflozinvs Placebo
relative difference 50% (95% CI 42–58)
As reported in the abstract
Further findings
| Outcome | Reduction in eGFR (mL/min per 1.73 m²) (95% CI) |
|---|---|
| Acute eGFR change · first 2 monthsEquivalent to a 6% (5-6) dip | 2.12 (1.83–2.41) |
Chronic slope reduction by baseline uACR subgroup
- Relative reduction in chronic slope, uACR <30 mg/g
- 86% [36-136]
- Relative reduction in chronic slope, uACR ≥2000 mg/g
- 29% [19-38]
- Trend across uACR
- P for trend < 0.0001
- Absolute and relative benefits on chronic slope varied significantly by diabetes status and baseline eGFR and uACR; absolute difference lower with lower baseline uACR
Original publication
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol. Published 4 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →